Meet the Scientists series - Meer Dr Jason Geue, R& D Manager at Agilex Biolabs.
Agilex Biolabs, Australia’s most experienced and technologically advanced bioanalytical laboratory and the only biolab in the region with a dedicated toxicology unit, has been selected as a finalist for the Most Successful Early Phase Research (Preclinical & Phase I) category in the Citeline Awards 2021.
https://youtu.be/dnyLFRPLEJo...
Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials is showcasing its new $1.5m vaccine and immunobiology laboratory at BIO Asia Taiwan 2021. The facility, the most sophisticated in APAC, is designed for biotechs and pharma from around the world for advanced clinical research including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials announced for BIO Korea 2021 that their upgraded and expanded biolabs at the Australian headquarters is now complete.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
Inflammation is a complex biological process involving a host of resident and recruited immune cells which are mobilized to infiltrate tissues in response to invading pathogens. These immune cells boast elevated numbers and heightened activation as they churn out inflammatory mediators, which act in unison to coordinate and modulate the immune response.
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials is partnering with Endpoints News to share the latest on deconvoluting inflammation and immunology for clinical trials, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
Demand for APAC clinical trials is still on the rise as COVID numbers continue to fall across the region attracting biotechs wanting to restart stalled or paused clinical trials from around the globe. Indeed Australia recorded zero new cases in the past 25 days.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Register here (free)...
Agilex Biolabs, the leading APAC biolabs for biotech clinical trials, announced today the launch of a Client Portal named GALEXI™.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
Title: Development and Validation of a PK Method for Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform
Agilex Biolabs, Australia’s most advanced specialist bioanalytical laboratory for clinical trials, congratulated client Zelira Therapeutics on their Phase 2 Medicinal Cannabis Insomnia Study.
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.